Immunovant

NSQ:IMVT · US45258J1025

BiotechnologySmall

360° View

Value43

Price/Sales3

Price/Earnings79

Price/Book5

Dividend Yield1

Growth64

Revenue Growth—

Profit Growth6

Capital Growth100

TSR 52w89

Safety76

Leverage97

Liquidity46

Refinancing42

Combined86

Sentiment77

Analyst Opinions38

Pro Holdings65

Opinion Changes50

Market Pulse77

Profile

CountryUK

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Employees315

Websiteimmunovant.com

ISINUS45258J1025

Last UpdateApr 2, 2026

Index & Theme

InflammationDermatologyEndocrinologyNeurologyChronic DiseasesImmunologyRheumatologyBiotechnologyPharmaceutical

Description

Immunovant, Inc. (‘Immunovant’) operates as a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. The company’s focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibi…

Analysis

Immunovant's 360° View rank of 86 places it among the strongest overall — better than 86% of its true peers.

It's growing solidly (64) and on the expensive side (43). On safety it is very well financed (76), and the market shows strongly positive sentiment (77). Taken together, its Combined rank of 86 reads as among the strongest overall.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Immunovant with its peers

Roivant Sciences

NSQ:ROIV

CountryUK

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Innate Pharma

PAR:IPH

CountryFrance

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Oculis Holding

NMQ:OCS

CountrySwitzerland

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Kuros Biosciences

SWX:KURN

CountrySwitzerland

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

OKYO Pharma

NAQ:OKYO

CountryUK

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Genmab

CPH:GMAB

CountryDenmark

IndustryBiotechnology

SizeLarge

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →